Related Experiment Video
Updated: Jul 1, 2026
07:51
Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro
Published on: March 18, 2019
Isoschaftoside Inhibits Osteoclastogenesis by Suppressing the NF-κB and MAPK Pathways.
Jangmi Yun1, Ki Yong Lee2,3, Byoungduck Park1
1College of Pharmacy, Sahmyook University, Seoul 01795, Republic of Korea.
Biomolecules & Therapeutics
|June 30, 2026
Summary
Isoschaftoside (ISH), derived from Viola yedoensis, inhibits osteoclastogenesis by blocking RANKL-induced NF-κB and MAPK signaling. This finding offers potential therapeutic strategies for bone resorption disorders.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Bone remodeling relies on a balance between formation and resorption.
- Osteoclast-driven bone resorption underlies bone homeostasis disruption and related disorders.
- Osteoclastogenesis, the differentiation of osteoclasts, is regulated by M-CSF and RANKL signaling pathways, including NF-κB and MAPK.
Purpose of the Study:
- To investigate the effect of Isoschaftoside (ISH), a flavonoid from Viola yedoensis, on osteoclastogenesis.
- To explore ISH's potential role in modulating RANKL-induced signaling pathways crucial for osteoclast differentiation.
Main Methods:
- Examined the impact of ISH on RANKL- and M-CSF-stimulated osteoclastogenesis.
- Assessed the effect of ISH on RANKL-induced activation of NF-κB and MAPK signaling pathways.
Main Results:
- Isoschaftoside (ISH) was found to attenuate RANKL-induced activation of both NF-κB and MAPK signaling.
- ISH significantly inhibited osteoclastogenesis and bone resorption.
- These inhibitory effects were observed in RANKL- and M-CSF-stimulated conditions.
Conclusions:
- Isoschaftoside (ISH) demonstrates potent inhibitory effects on osteoclastogenesis and bone resorption.
- ISH's mechanism involves the suppression of key signaling pathways, NF-κB and MAPK, activated by RANKL.
- These findings suggest ISH as a potential therapeutic agent for managing bone resorption-related diseases.
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
02:26NF-kB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...